Global Live Biotherapeutic Product (LBP) Market

Report ID : 1300 | Published : 2022-08-02 | Pages: 175 | Format: PDF/EXCEL

Live Biotherapeutic Product (LBP) Market is valued at US$ 355.97 Mn in 2021 with a CAGR of 25.2% during a forecast period of 2022-2030. A live microbe is utilized in a Live Biotherapeutic product to treat, prevent, or cure a disease. Microorganisms that may be beneficial to health have been discovered as the human microbiome, and its relationship to human health has come to be better understood. These microorganisms have a lot of potential for use as Live Biotherapeutic products in clinical settings. Several clinical trials are being conducted to assess their potential as a treatment. LBPs are believed to have biological effects by modulating the host-microbiota rather than directly acting on known targets or distant organs, tissues, or receptors. Importantly, LBPs will have a biological effect by influencing the local ecosystem, other microorganisms, and their interactions with the host.

Throughout the forecast period, market growth is anticipated to be driven by rising research and development efforts, as well as an expanding pipeline of microbiome-targeting therapies that are anticipated to treat a wide range of serious diseases. The development of new drugs and clinical trial activities for the treatment of diseases are being aided by ongoing innovation and technological advancements. In 2019, 4D pharma collaborated with MSD to research and develop Live Biotherapeutics for vaccines. 4D's proprietary MicroRx® platform will be combined with MSD's expertise in developing and commercializing novel vaccines. During the forecast period, significant growth opportunities are anticipated as government funding and the R&D budget for drug development both increases. Over 640 patents focused on microbiome therapeutics were approved in 2020. The complexities occur due to a lack of expertise, specialized infrastructure, the need for astronomical capital expenditures, capacity limitations, and restrictions on ensuring compliance with good manufacturing practices (GMP).

The Live Biotherapeutic Product Market is segmented into five main categories Type of Product, Type of Molecule, Target disease indication, Therapeutic area and route of administration. Type of Product consists of Probiotic drugs and other drugs in which probiotic drugs are in demand for good health. By Type of Molecule, it is divided into small molecules and Biologics. Distribution of market by Target disease indication includes Graft Versus Host Disease, Necrotizing Enterocolitis, Primary Hyperoxaluria, Recurrent C. difficile Infection and Other indications. By means of the Therapeutic area, the market is sub-divided into Digestive and Gastrointestinal Disorders, Infectious Diseases, Rare Disorders, and Others. The last and one of the essential segments is the route of administration, categorized into Oral therapeutics and Rectal therapeutics.

Regionally, North America is anticipated to experience brisk growth during the forecast period (2022-2030) as a result of rising demand and the significant COVID-19 effect. Large sums of money are given to businesses to research Live Biotherapeutic ingredients and create new products.

Important Live Biotherapeutic products market players are 4D pharma plc, Seres Therapeutics, Inc., Microbiotica, Enterome, Destiny Pharma plc, Taisho Pharmaceutical Holdings, AOBiome Therapeutics, Inc., Finch Therapeutics Group, Inc, Ferring Pharmaceuticals, Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals), MaaT Pharma, Vedanta Biosciences Inc., OxThera AB, Pendulum Therapeutics, Caelus Health, Quorum Innovations, Sanofi S.A, DermBiont, Inc., EnteroBiotix Ltd, YSOPIA Bioscience, Winclove Probiotics, TargEDys, Evelo Biosciences, Inc., BiomX, Biomica Ltd., Scioto Biosciences, Inc., Lactobio A/S, Takeda Pharmaceutical Co. Ltd., Second Genome Therapeutics, Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Immuron Limited, Naked Biome, Synthetic Biologics, ExeGi Pharma, Nexbiome, Mybiotics Pharma LTD and others.

  • 4D pharma plc
  • Seres Therapeutics, Inc.
  • Microbiotica
  • Enterome
  • Destiny Pharma plc
  • Taisho Pharmaceutical Holdings
  • AOBiome Therapeutics, Inc.
  • Finch Therapeutics Group, Inc
  • Ferring Pharmaceuticals
  • Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)
  • MaaT Pharma
  • Vedanta Biosciences Inc.
  • OxThera AB
  • Pendulum Therapeutics
  • Caelus Health
  • Quorum Innovations
  • Sanofi S.A
  • DermBiont, Inc.
  • EnteroBiotix Ltd
  • YSOPIA Bioscience
  • Winclove Probiotics
  • TargEDys
  • Evelo Biosciences, Inc.
  • BiomX
  • Biomica Ltd.
  • Scioto Biosciences, Inc.
  • Lactobio A/S
  • Takeda Pharmaceutical Co. Ltd.
  • Second Genome Therapeutics
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
  • PureTech Health Plc
  • Immuron Limited
  • Naked Biome
  • Synthetic Biologics
  • ExeGi Pharma
  • Nexbiome
  • Mybiotics Pharma LTD

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Live biotherapeutic Product (LBP) Market Snapshot

Chapter 4. Global Live biotherapeutic Product (LBP) Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Products, Estimates & Trend Analysis

5.1. By Products, & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

5.2.1. Probiotic Drugs

5.2.2. Other Drugs

Chapter 6. Market Segmentation 2: By Molecules Estimates & Trend Analysis

6.1. By Molecules & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Molecules:

6.2.1. Small Molecules

6.2.2. Biologics

Chapter 7. Market Segmentation 3: By Target Disease Indication Estimates & Trend Analysis

7.1. By Target Disease Indication & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Target Disease Indication:

7.2.1. Graft Versus Host Disease

7.2.2. Necrotizing Enterocolitis

7.2.3. Primary Hyperoxaluria,

7.2.4. Recurrent C. difficile Infection

7.2.5. Other Target Disease Indication

Chapter 8. Market Segmentation 4: By Therapeutic Area Estimates & Trend Analysis

8.1. By Therapeutic Area & Market Share, 2020& 2030

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Therapeutic Area:

8.2.1. Digestive and Gastrointestinal Disorders

8.2.2. Infectious Diseases

8.2.3. Rare Disorders

8.2.4. Other Therapeutic Area

Chapter 9. Market Segmentation 5: By Route of Administration Estimates & Trend Analysis

9.1. By Route of Administration & Market Share, 2020& 2030

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Route of Administration:

9.2.1. Oral Therapeutics

9.2.2. Rectal Therapeutics

Chapter 10. Live biotherapeutic Product (LBP) Market Segmentation 6: Regional Estimates & Trend Analysis

10.1. North America

10.1.1. North America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Products, 2019-2030

10.1.2. North America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Molecules, 2019-2030

10.1.3. North America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Target Disease Indication, 2019-2030

10.1.4. North America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2019-2030

10.1.5. North America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2030

10.1.6. North America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

10.2. Europe

10.2.1. Europe Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Products, 2019-2030

10.2.2. Europe Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Molecules, 2019-2030

10.2.3. Europe Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Target Disease Indication, 2019-2030

10.2.4. Europe Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2019-2030

10.2.5. Europe Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2030

10.2.6. Europe Live biotherapeutic Product (LBP) Market revenue (US$ Million) by country, 2019-2030

10.3. Asia Pacific

10.3.1. Asia Pacific Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Products, 2019-2030

10.3.2. Asia Pacific Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Molecules, 2019-2030

10.3.3. Asia Pacific Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Target Disease Indication, 2019-2030

10.3.4. Asia Pacific Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2019-2030

10.3.5. Asia Pacific Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2030

10.3.6. Asia Pacific Live biotherapeutic Product (LBP) Market revenue (US$ Million) by country, 2019-2030

10.4. Latin America

10.4.1. Latin America Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

10.4.2. Latin America Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Molecules, (US$ Million) 2019-2030

10.4.3. Latin America Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Target Disease Indication, (US$ Million) 2019-2030

10.4.4. Latin America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2019-2030

10.4.5. Latin America Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2030

10.4.6. Latin America Live biotherapeutic Product (LBP) Market revenue (US$ Million) by country, 2019-2030

10.5. Middle East & Africa

10.5.1. Middle East & Africa Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

10.5.2. Middle East & Africa Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Molecules, (US$ Million) 2019-2030

10.5.3. Middle East & Africa Live biotherapeutic Product (LBP) Market revenue (US$ Million) By Target Disease Indication, (US$ Million) 2019-2030

10.5.4. Middle East & Africa Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2019-2030

10.5.5. Middle East & Africa Live biotherapeutic Product (LBP) Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2030

10.5.6. Middle East & Africa Live biotherapeutic Product (LBP) Market revenue (US$ Million) by country, 2019-2030

Chapter 11. Competitive Landscape

11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles

11.2.1. 4D pharma plc

11.2.2. Seres Therapeutics, Inc.

11.2.3. Microbiotica

11.2.4. Enterome

11.2.5. Destiny Pharma plc

11.2.6. Taisho Pharmaceutical Holdings

11.2.7. AOBiome Therapeutics, Inc.

11.2.8. Finch Therapeutics Group, Inc

11.2.9. Ferring Pharmaceuticals

11.2.10. Rebiotix Inc. (A Subsidiary of Ferring Pharmaceuticals)

11.2.11. MaaT Pharma

11.2.12. Vedanta Biosciences Inc.

11.2.13. OxThera AB

11.2.14. Pendulum Therapeutics

11.2.15. Caelus Health

11.2.16. Quorum Innovations

11.2.17. Sanofi S.A

11.2.18. DermBiont, Inc.

11.2.19. EnteroBiotix Ltd

11.2.20. YSOPIA Bioscience

11.2.21. Winclove Probiotics

11.2.22. TargEDys

11.2.23. Evelo Biosciences, Inc.

11.2.24. BiomX

11.2.25. Biomica Ltd.

11.2.26. Scioto Biosciences, Inc.

11.2.27. Lactobio A/S

11.2.28. Takeda Pharmaceutical Co. Ltd.

11.2.29. Second Genome Therapeutics

11.2.30. Johnson and Johnson Inc.

11.2.31. Kaleido Biosciences Inc.

11.2.32. OptiBiotix Health Plc

11.2.33. PureTech Health Plc

11.2.34. Immuron Limited

11.2.35. Naked Biome

11.2.36. Synthetic Biologics

11.2.37. ExeGi Pharma

11.2.38. Nexbiome

11.2.39. Mybiotics Pharma LTD

11.2.40. Axial Therapeutics, Inc.

11.2.41. BrickBuilt Therapeutics

11.2.42. Siolta Therapeutics

11.2.43. VastBiome

11.2.44. Destiny Pharma

11.2.45. Gusto Global LLC

11.2.46. Stellate Therapeutics

11.2.47. Sciotio Biosciences Inc

11.2.48. Rise Therapeutics

11.2.49. EverImmune S.A.

11.2.50. Other Prominent Players

Global Live Biotherapeutic Product (LBP) Market, by Type Of Product, 2022-2030 (Value US$ Mn)

  • Probiotic Drugs
  • Other Drugs

Global Live Biotherapeutic Product (LBP) Market, by Type of Molecule, 2022-2030 (Value US$ Mn)

  • Small Molecules
  • Biologics

Global Live Biotherapeutic Product (LBP) Market, by Target disease indication, 2022-2030 (Value US$ Mn)

  • Graft Versus Host Disease
  • Necrotizing Enterocolitis
  • Primary Hyperoxaluria,
  • Recurrent C. difficile Infection
  • Others

Global Live Biotherapeutic Product (LBP) Market, by Therapeutic area, 2022-2030 (Value US$ Mn)

  • Digestive and Gastrointestinal Disorders
  • Infectious Diseases
  • Rare Disorders
  • Others

Global Live Biotherapeutic Product (LBP) Market, by Route of administration, 2022-2030 (Value US$ Mn)

  • Oral Therapeutics
  • Rectal Therapeutics

Global Live Biotherapeutic Product (LBP) Market, by Region, 2022-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Live Biotherapeutic Product (LBP) Market, by Country, 2022-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Live Biotherapeutic Product (LBP) Market?

CAGR of 25.2% during a forecast period of 2022-2030

Our Clients